Mirati fires its CEO
Mirati fires its CEO and announces a new lung cancer Krazati-Keytruda study strategy
SG Tylor
Following the successful approval of the KRAS inhibitor Krazati, Mirati Therapeutics’ CEO David Meek has made an abrupt exit from ...